Form 4: Enliven Therapeutics CEO Samuel Kintz Sells Shares Under 10b5-1 Trading Plan

Enliven Therapeutics' CEO, Samuel Kintz, executed multiple sales of common stock on July 25, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Samuel Kintz, CEO of Enliven Therapeutics, sold shares of common stock on July 25, 2024.
• The sales were executed under a Rule 10b5-1 trading plan adopted on June 26, 2023.
• A total of 11,990 shares were sold in multiple transactions at varying prices.
• The weighted average sale prices were $24.53, $25.1004, and $25.8295 per share for the respective transactions.
• Following the reported transactions, Kintz directly owns no shares, but indirectly owns 1,063,525 shares through The Kintz & Egan Trust, 88,531 shares through a trust for his elder son, and 88,531 shares through a trust for his younger son.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports stock sales under a pre-existing trading plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Insider selling can sometimes be viewed negatively by the market, but the existence of a pre-arranged 10b5-1 trading plan often mitigates this concern as it indicates the sales were planned in advance and not based on current, non-public information.

Stakeholder Impact

• The stock sale could have a minor negative impact on shareholder sentiment, although the existence of a 10b5-1 plan may lessen this effect.

Key Dates